Leal Therapeutics
Develops neuro-metabolic therapeutics for schizophrenia and ALS
$30MSeries A
Role not disclosedNP
Newpath Partners
Activity from announced rounds
Activity in this selectionearlybird-venture-capital-327ce1a4
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $152M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionCREATE Medicines
Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies
$122MSeries B
Role not disclosed